SELLAS Life Sciences CEO sells 26,606 shares for taxes
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
SELLAS Life Sciences Group, Inc. (SLS) President and CEO Angelos M. Stergiou reported a sale of 26,606 shares at $19.1780 per share on November 18, 2026. The sale satisfied tax withholding when previously granted performance-based restricted stock units vested after the primary endpoint was met in the Phase 3 REGAL study. The company’s equity plans require this “sell to cover” mechanism; the footnote says the sale was not discretionary. Stergiou directly held 1,734,896 shares after the transaction.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1 | 26,606 | $19.178 | $510K |
Footnotes (1)
- F1. Represents shares sold to satisfy the Reporting Person's tax withholding obligation in connection with the performance based vesting of certain previously granted restricted stock units upon meeting the primary endpoint in the Issuer's Phase 3 REGAL study. These sales are mandated as part of the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Key Figures
Key Terms
restricted stock units financial
sell to cover financial
tax withholding obligation financial
primary endpoint medical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.